CLRB Stock Analysis: Buy, Sell, or Hold?
CLRB - Cellectar Biosciences INC NEW
$2.60
-0.14 (-5.11%)
▼
5d:
-17.2%
30d:
-8.13%
90d:
-10.34%
WAIT
LOW Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: May 12, 2026
0d
Get Alerted When CLRB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
3 traders called CLRB this week
75% bullish • 1 bearish
75% bullish • 1 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: CLRB is down 17.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: CLRB is down 17.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: CLRB is currently trading at $2.60, which is considered oversold relative to its 30-day fair value range of $2.74 to $3.24.
Technical Outlook: Technically, CLRB is in a downtrend. The price is currently testing key support at $2.57. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.1% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $10.33 (+297.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CLRB is in a downtrend. The price is currently testing key support at $2.57. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.1% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $10.33 (+297.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.74 -
$3.24
Company Quality Score
53/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
72.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BEARISH: Downward momentum (-5.1%)
- BULLISH: Trading 297.4% below Wall St target ($10.33)
- WARNING: Recommendation downgraded due to -17.2% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$2.74 -
$3.24
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.57
Resistance Level
$3.29
Current Trend
Downtrend
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.62
Wall Street Target
$10.33
(+297.4%)
Share & Embed Analysis
Last updated: June 03, 2026 6:54 PM ET
Data refreshes hourly during market hours. Next update: 7:54 PM
Data refreshes hourly during market hours. Next update: 7:54 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CLRB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
John Neis
SELL
198 shares
2025-12-12
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1023 | 53 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$82 | 58 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$297 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 48 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
BUY
20 analysts |
$32 | 59 HOLD |
